VolitionRX (NYSEAMERICAN:VNRX – Get Free Report) was downgraded by equities research analysts at Freedom Broker from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, MarketBeat.com reports.
Separately, Benchmark reiterated a “hold” rating on shares of VolitionRX in a research report on Monday, August 17th. Two research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $28.00.
Get Our Latest Stock Report on VolitionRX
VolitionRX Trading Down 5.6%
VolitionRX (NYSEAMERICAN:VNRX – Get Free Report) last posted its earnings results on Thursday, November 12th. The medical research company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.18. The business had revenue of $1.61 million during the quarter, compared to the consensus estimate of $0.71 million. As a group, research analysts forecast that VolitionRX will post -1.55 EPS for the current fiscal year.
About VolitionRX
VolitionRx Ltd. is a diagnostics company developing blood-based tests for cancer and other diseases. Its Nu.Q technology measures nucleosomes—DNA-protein structures released into the bloodstream—as potential biomarkers for detecting and monitoring disease. The company is developing Nu.Q tests for human health applications and has also pursued veterinary diagnostics, including Nu.Q Vet tests intended to help identify cancer in dogs. Its products and programs are at varying stages of development and commercialization.
Further Reading
- Five stocks we like better than VolitionRX
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.
